Michael W Drazer
Overview
Explore the profile of Michael W Drazer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Patel A, Rojek A, Drazer M, Weiner H, Godley L, Le Beau M, et al.
Blood Adv
. 2021 Sep;
5(20):4140-4148.
PMID: 34492705
Therapy-related myeloid neoplasms (t-MNs) are a late complication of cytotoxic therapy and are defined as a distinct entity by the World Health Organization. Although the link between chemotherapy exposure and...
22.
Homan C, King-Smith S, Lawrence D, Arts P, Feng J, Andrews J, et al.
Haematologica
. 2021 Jul;
106(11):3004-3007.
PMID: 34233450
No abstract available.
23.
Borst S, Nations C, Klein J, Pavani G, Maguire J, Camire R, et al.
Stem Cell Reports
. 2021 May;
16(6):1458-1467.
PMID: 34019812
Inherited thrombocytopenia results in low platelet counts and increased bleeding. Subsets of these patients have monoallelic germline mutations in ETV6 or RUNX1 and a heightened risk of developing hematologic malignancies....
24.
Roloff G, Godley L, Drazer M
Genet Med
. 2020 Aug;
23(1):211-214.
PMID: 32807974
Purpose: To determine the degree of testing consistency among commercially available diagnostic assays for hereditary hematopoietic malignancies (HHMs). Methods: Next-generation sequencing assays designed for the diagnosis of HHMs were studied...
25.
Akpan I, Osman A, Drazer M, Godley L
Curr Hematol Malig Rep
. 2018 Sep;
13(6):426-434.
PMID: 30259338
Purpose Of Review: To review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions...
26.
27.
Tawana K, Drazer M, Churpek J
Leukemia
. 2018 Feb;
32(7):1482-1492.
PMID: 29483711
Comprehensive genomic profiling of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) cases have enabled the detection and differentiation of driver and subclonal mutations, informed risk prognostication, and defined targeted...
28.
Drazer M, Kadri S, Sukhanova M, Patil S, West A, Feurstein S, et al.
Blood Adv
. 2018 Jan;
2(2):146-150.
PMID: 29365323
Next-generation sequencing (NGS)-based targeted gene capture panels are used to profile hematopoietic malignancies to guide prognostication and treatment decisions. Because these panels include genes associated with hereditary hematopoietic malignancies (HHMs),...
29.
Feurstein S, Drazer M, Godley L
Semin Oncol
. 2016 Dec;
43(5):598-608.
PMID: 27899193
In this review, we provide an overview of familial myelodysplastic syndromes (MDS)/acute leukemia (AL) and bone marrow failure syndromes, as well as insights into familial myeloproliferative neoplasms (MPNs), familial multiple...
30.
Drazer M, Stadler W
Cancer J
. 2016 Oct;
22(5):330-333.
PMID: 27749326
Most men with metastatic prostate cancer who are treated with androgen deprivation therapy will eventually develop castration-resistant disease. In this review, we examine the molecular mechanisms that constitute castration resistance...